When nystatin is placed in RPMI and other biological fluids, there is loss of pure nystatin, with the development of two distinguishable chromatographic peaks, 1 and 2. Peak 1 appears identical to commercially prepared nystatin. By nuclear magnetic resonance (NMR) and mass spectral analysis, peak 2 appears to be an isomer of peak 1. The isomers are quantitatively and fully interconvertible. Formation of peak 2 is accelerated at a pH of >7.0 and ultimately reaches a near 55:45 (peak 1/peak 2 ratio) mixture. We sought to determine the relative activities of peaks 1 and 2 against Candida spp. Peak 2 consistently showed higher MICs when it was the predominant form during the experiment. Time-kill analyses showed that peak 2 required >8؋ the concentration of peak 1 to produce a modest and delayed killing effect, which was never of the same magnitude as that produced by peak 1. In both types of assays, the activity of peak 2 corresponded with intra-assay formation of peak 1. Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1.Life-threatening fungal infections have become increasingly prevalent among patients with human immunodeficiency virus or AIDS, patients with cancer, transplant recipients, and patients in intensive care units (1, 2-4, 6, 10). Therapeutic options are often limited by the toxicity of currently available systemic antifungal agents and the emergence of resistance (9,24,25). This has prompted the development of new antifungal agents, as well as the "rediscovery" and "reengineering" of agents where use had been limited due to toxicity (16).Nystatin is a polyene-macrolide antifungal antibiotic produced by Streptomyces noursei that was discovered and developed in the 1950s (18). It is now widely available for the topical treatment of localized fungal infections. Toxicity problems prevented its use as a systemic agent, but recently developed liposomal delivery technologies have made it an attractive candidate for the treatment of severe systemic fungal infections (12,16,17,20,26; C. J. Jessup, T. J. Wallace, and M. A. Ghannoum, 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-88, p. 161, 1997). This has prompted new investigations of its antifungal properties and spectrum as well as its physicochemical and pharmacokinetic characteristics (5, 7, 11, 15; S. Arikan, M. Lozano-Chiu, V. Paetznick, D. Gordon, T. Wallace, and J. H. Rex, Abstr. 98th Gen. Meet. Am. Society Microbiol., abstr. C-280, p. 178, 1998).Commercially prepared nystatin appears as a single, highly pure chromatographic peak (hereinafter referred as peak 1) while in an organic solvent. However, when placed in a biological matrix, such as human plasma or culture medium, chromatographic analysis yields a second peak that elutes after the pure peak seen from nystatin stored in an organic solvent. Earlier work (data on file at Aronex Pharmaceuticals) suggested that the appearance of this second peak, termed peak ...